39,093 Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) Purchased by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC acquired a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 39,093 shares of the company's stock, valued at approximately $543,000. Susquehanna Fundamental Investments LLC owned about 0.08% of Tyra Biosciences as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Rhumbline Advisers grew its holdings in shares of Tyra Biosciences by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock valued at $364,000 after purchasing an additional 1,027 shares during the period. Barclays PLC increased its holdings in shares of Tyra Biosciences by 200.5% during the 3rd quarter. Barclays PLC now owns 37,625 shares of the company's stock worth $884,000 after buying an additional 25,106 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Tyra Biosciences by 1.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company's stock valued at $8,667,000 after buying an additional 3,896 shares during the period. Raymond James Financial Inc. acquired a new position in Tyra Biosciences in the fourth quarter valued at approximately $761,000. Finally, Alta Partners Management Company L.P. purchased a new position in Tyra Biosciences in the fourth quarter worth approximately $56,716,000. Hedge funds and other institutional investors own 84.14% of the company's stock.

Tyra Biosciences Price Performance

Tyra Biosciences stock traded up $0.03 during midday trading on Friday, hitting $10.10. 168,050 shares of the stock were exchanged, compared to its average volume of 257,500. Tyra Biosciences, Inc. has a 1 year low of $6.42 and a 1 year high of $29.60. The company has a 50 day moving average price of $9.66 and a two-hundred day moving average price of $13.43. The firm has a market cap of $536.21 million, a P/E ratio of -6.27 and a beta of 1.17.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. As a group, analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on TYRA shares. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Tyra Biosciences in a research report on Monday, March 31st. Wedbush reiterated an "outperform" rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, March 28th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tyra Biosciences currently has an average rating of "Buy" and a consensus target price of $30.83.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.